Indegene Ltd

Indegene Ltd announced an update on a material litigation involving its wholly-owned subsidiary, Indegene, Inc. The class-action lawsuit, filed under the U.S. Telephone Consumer Protection Act, 1991 (TCPA), alleged violations concerning certain fax communications in February 2020. Following class certification and denial of appeal, parties entered mediation and negotiated settlement terms. Negotiations on the definitive settlement agreement are substantially concluded, with the company authorizing its execution. The settlement, subject to final execution and court approval, does not admit liability. The maximum settlement fund is approximately USD 4.72 million, calculated at USD 250 per eligible fax/claim. The actual payout depends on the number of valid claims submitted.

Indegene Limited conducted its 28th Annual General Meeting (AGM) on August 13, 2026, via video conferencing. The meeting was held in compliance with SEBI regulations, and the transcript is now available on the company's website. Key management personnel, including Chairman Manish Gupta, Executive Director Dr. Sanjay Suresh Parikh, CFO Suhas Prabhu, and Company Secretary Srishti Ramesh Kaushik, were present. The AGM focused on shareholder engagement and company governance, with provisions for electronic voting through NSDL.

Indegene Ltd announced the appointment of Ms. Jill Mary De Simone as an Independent Director, approved by shareholders at the 28th Annual General Meeting held on August 13, 2026. Ms. De Simone's term is for three years, effective January 22, 2026, to January 21, 2029. She brings extensive experience from leadership roles in biopharmaceutical companies like Merck, Teva, and Bristol Myers Squibb, with expertise in oncology, HIV, and general medicine. Currently, she advises life sciences companies and serves on boards, focusing on commercialization and AI in healthcare. She is not related to any existing director and is not debarred from holding a directorship.

BPC Genesis Fund I-A SPV Limited has disclosed the sale of its entire holding of 7,190,255 equity shares in Indegene Limited, representing 2.986% of the total share capital. The sale was executed via open market transactions on the NSE (Capital Market Segment) on August 6, 2026. Following the sale, BPC Genesis Fund I-A SPV Limited holds no shares in Indegene Limited. The disclosure was made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

BPC Genesis Fund I SPV Ltd has disclosed the sale of its entire stake in Indegene Limited, amounting to 13,862,223 equity shares. This represents 5.757% of the total share capital and 5.741% of the total diluted share capital. The sale was conducted via open market transactions on the NSE. Following this transaction, BPC Genesis Fund I SPV Ltd holds no shares in Indegene Limited. The disclosure was made under SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Indegene announced its financial results for the quarter ended June 30, 2026, reporting a strong Q1 FY27 performance. Revenue from operations stood at ₹10,631 million, a significant year-over-year increase of 39.7% (26.5% in USD terms) and 6.0% sequentially. EBITDA was ₹1,795 million with a margin of 16.9%, up 8.9% QoQ. Profit After Tax (PAT) reached ₹1,162 million, a 45.9% QoQ increase, with a margin of 10.9%. The company also saw its active client base cross the 100-milestone, reaching 105, with 12 customers now in the $10M+ revenue range. Revenue per Employee (RPE) improved to $77.1K, noted as the highest among peers.

Indegene Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026. The report, issued by Care Edge Ratings, confirms the utilization of IPO proceeds aggregating to ₹760.00 crores. The monitoring agency found no deviation from the objects specified in the Offer Document and the revised objects approved by shareholders. The report covers the period of the Initial Public Offering (IPO) and details the utilization of funds as per SEBI regulations and the Monitoring Agency Agreement. The company does not have an identifiable promoter and operates in the Healthcare Services sector, focusing on Research, Analytics & Technology.

Indegene Limited announced its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The Board of Directors approved these results along with the Limited Review Report from the auditors, which had an unmodified opinion. Additionally, the company approved an allotment under its ESOP Scheme 2020. The trading window for designated persons will reopen on August 3, 2026. The financial results were prepared in accordance with Indian Accounting Standard 34 and other accepted accounting principles.

Indegene Limited's Board of Directors met on July 30, 2026, to approve the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026. The board also approved allotments under the ESOP Scheme 2020. The company's trading window for designated persons will reopen on August 3, 2026. The financial results were accompanied by a limited review report from the auditors with an unmodified opinion and a CFO declaration.

Indegene Ltd has initiated the dispatch of letters to shareholders who have not registered their email IDs, providing a weblink to access the Annual Report for the financial year 2025-26. This action complies with SEBI Listing Regulations. The 28th Annual General Meeting (AGM) is scheduled for August 13, 2026, via Video Conference. The company also reminds shareholders to update KYC details, including PAN, address, and bank information, especially for those holding physical securities, to ensure eligibility for payments like dividends. Shareholders are encouraged to register their email IDs for online services and to support green initiatives.